JPWO2022016270A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022016270A5 JPWO2022016270A5 JP2023504005A JP2023504005A JPWO2022016270A5 JP WO2022016270 A5 JPWO2022016270 A5 JP WO2022016270A5 JP 2023504005 A JP2023504005 A JP 2023504005A JP 2023504005 A JP2023504005 A JP 2023504005A JP WO2022016270 A5 JPWO2022016270 A5 JP WO2022016270A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- ligand
- antigen
- receptor
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063054180P | 2020-07-20 | 2020-07-20 | |
| US63/054,180 | 2020-07-20 | ||
| US202163172626P | 2021-04-08 | 2021-04-08 | |
| US63/172,626 | 2021-04-08 | ||
| PCT/CA2021/051006 WO2022016270A1 (en) | 2020-07-20 | 2021-07-20 | Fusion proteins comprising a ligand-receptor pair and a biologically functional protein |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023541771A JP2023541771A (ja) | 2023-10-04 |
| JPWO2022016270A5 true JPWO2022016270A5 (https=) | 2024-07-29 |
| JP2023541771A5 JP2023541771A5 (https=) | 2024-07-29 |
| JP7846668B2 JP7846668B2 (ja) | 2026-04-15 |
Family
ID=79729591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504005A Active JP7846668B2 (ja) | 2020-07-20 | 2021-07-20 | リガンド－受容体対及び生物学的に機能的なタンパク質を含む融合タンパク質 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230331809A1 (https=) |
| EP (1) | EP4182357A4 (https=) |
| JP (1) | JP7846668B2 (https=) |
| KR (1) | KR20230042315A (https=) |
| CN (1) | CN116171167B (https=) |
| AU (1) | AU2021312554A1 (https=) |
| CA (1) | CA3145387A1 (https=) |
| MX (1) | MX2023000839A (https=) |
| WO (1) | WO2022016270A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7773991B2 (ja) * | 2020-03-23 | 2025-11-20 | ザイムワークス ビーシー インコーポレイテッド | マスクされたｉｌ１２融合タンパク質及びその使用方法 |
| WO2023141713A1 (en) * | 2022-01-26 | 2023-08-03 | Zymeworks Bc Inc. | Immunomodulatory trispecific t cell engager fusion proteins |
| US20240254223A1 (en) * | 2022-09-02 | 2024-08-01 | Novimmune Sa | Reciprocally masked antibody-cytokine fusion proteins and methods of use thereof |
| AU2023366004A1 (en) * | 2022-10-19 | 2025-06-05 | Zymeworks Bc Inc. | Trivalent and trispecific antibody constructs and methods of use thereof |
| CN116574748B (zh) * | 2023-07-10 | 2023-09-12 | 昆明医科大学 | 一种用于靶向KRAS高频突变肿瘤的嵌合型nTCR-T构建方法 |
| AU2024330202A1 (en) * | 2023-08-25 | 2026-02-12 | Ibio, Inc. | High-efficiency, conditionally-activated antibody discovery and masked antibodies |
| WO2025117851A1 (en) * | 2023-11-30 | 2025-06-05 | The General Hospital Corporation | Meso-fap with adam17 inhibitor or itk inhibitor |
| WO2025133042A2 (en) * | 2023-12-22 | 2025-06-26 | F. Hoffmann-La Roche Ag | Activatable fusion proteins and methods of use |
| WO2025170315A1 (ko) * | 2024-02-05 | 2025-08-14 | 주식회사 트리오어 | 이중 기능 도메인을 포함하는 융합단백질 및 이의 용도 |
| KR20250161096A (ko) * | 2024-05-07 | 2025-11-17 | 바이티디 주식회사 | Vista 및 msln에 특이적으로 결합하는 이중특이적 항체 및 이의 용도 |
| WO2025247847A1 (en) | 2024-05-30 | 2025-12-04 | Zytox Therapeutics Ab | A matriptase-cleavable substrate |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201608307WA (en) | 2012-04-20 | 2016-11-29 | Emergent Product Dev Seattle | Cd3 binding polypeptides |
| WO2015095404A2 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
| HRP20230528T1 (hr) | 2016-03-22 | 2023-08-04 | F. Hoffmann - La Roche Ag | Bispecifične molekule t stanica aktivirane proteazom |
| EP3625253A4 (en) * | 2017-05-16 | 2021-03-24 | Scalmibio, Inc. | ACTIVABLE ANTIBODIES AND THEIR METHODS OF USE |
| WO2019080883A1 (en) | 2017-10-26 | 2019-05-02 | Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd. | NOVEL RECOMBINANT FUSION PROTEINS, PREPARATION THEREOF AND USE THEREOF |
| CA3120800A1 (en) * | 2018-12-17 | 2020-06-25 | Revitope Limited | Twin immune cell engager |
-
2021
- 2021-07-20 CN CN202180051531.1A patent/CN116171167B/zh active Active
- 2021-07-20 CA CA3145387A patent/CA3145387A1/en active Pending
- 2021-07-20 JP JP2023504005A patent/JP7846668B2/ja active Active
- 2021-07-20 MX MX2023000839A patent/MX2023000839A/es unknown
- 2021-07-20 AU AU2021312554A patent/AU2021312554A1/en active Pending
- 2021-07-20 WO PCT/CA2021/051006 patent/WO2022016270A1/en not_active Ceased
- 2021-07-20 KR KR1020237005797A patent/KR20230042315A/ko active Pending
- 2021-07-20 US US18/017,319 patent/US20230331809A1/en active Pending
- 2021-07-20 EP EP21845766.1A patent/EP4182357A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240233818A1 (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| US20240344046A1 (en) | Recombinant human sialidases, sialidase fusion proteins, and methods of using the same | |
| JPWO2022016270A5 (https=) | ||
| CN111867612B (zh) | 抗PDL1、IL-15和TGF-β受体组合分子 | |
| CN113840634B (zh) | 可活化蛋白质构建体及其用途 | |
| CN110799528B (zh) | 基于多聚体il-15的分子 | |
| ES2643835T3 (es) | Anticuerpos de unión a receptor de CGRP humano | |
| US12187763B2 (en) | Chromatography resin and uses thereof | |
| WO2019222282A1 (en) | Conditionally activated binding protein comprising a sterically occluded target binding domain | |
| CN110719918B (zh) | 靶向至少cd3和hsa的异源二聚体多特异性抗体形式 | |
| CA3108949A1 (en) | Multi-chain chimeric polypeptides and uses thereof | |
| TW202235438A (zh) | 能夠調節配體結合活性的配體結合分子 | |
| KR20230042315A (ko) | 리간드-수용체 쌍 및 생물학적 기능성 단백질을 포함하는 융합 단백질 | |
| US20230242676A1 (en) | Polypeptides, protein complexes and method for making same | |
| JP2026032063A (ja) | 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびその使用方法 | |
| JP2023532021A (ja) | プロテアーゼ感受性が低減された組換えシアリダーゼ、シアリダーゼ融合タンパク質、及びその使用方法 | |
| JPWO2020229553A5 (https=) | ||
| JP2025512798A (ja) | 活性化可能な二重アンカー型マスク化分子及びその使用方法 | |
| US20240400696A1 (en) | Compositions targeting epidermal growth factor receptor and methods for making and using the same | |
| JPWO2020123980A5 (https=) | ||
| CN119053622A (zh) | 一种抗ceacam5和ceacam6抗体及其应用 | |
| KR102705001B1 (ko) | 단백질 a 친화성 크로마토그래피를 이용한 생리활성 펩티드의 정제 방법 | |
| JPWO2021046331A5 (https=) | ||
| CN120018859A (zh) | 抗尿激酶型纤溶酶原激活物受体抗体及其使用方法 | |
| US20250066478A1 (en) | High-efficiency, conditionally-activated antibody discovery and masked antibodies |